Cargando…
PARP1 rs1805407 Increases Sensitivity to PARP1 Inhibitors in Cancer Cells Suggesting an Improved Therapeutic Strategy
Personalized cancer therapy relies on identifying patient subsets that benefit from a therapeutic intervention and suggest alternative regimens for those who don’t. A new data integrative approach, based on graphical models, was applied on our multi-modal –omics, and clinical data cohort of metastat...
Autores principales: | Abecassis, Irina, Sedgewick, Andrew J., Romkes, Marjorie, Buch, Shama, Nukui, Tomoko, Kapetanaki, Maria G., Vogt, Andreas, Kirkwood, John M., Benos, Panayiotis V., Tawbi, Hussein |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397203/ https://www.ncbi.nlm.nih.gov/pubmed/30824778 http://dx.doi.org/10.1038/s41598-019-39542-2 |
Ejemplares similares
-
MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603
por: Villaruz, Liza C., et al.
Publicado: (2015) -
Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies
por: Yélamos, José, et al.
Publicado: (2020) -
PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
por: Wang, Luyao, et al.
Publicado: (2017) -
Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
por: Maluchenko, Natalya, et al.
Publicado: (2022) -
PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
por: van Beek, Lotte, et al.
Publicado: (2021)